Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro

Alterations of fibroblast growth factor receptors (FGFRs) are common in bladder and other cancers and result in disrupted signalling via several pathways. Therapeutics that target FGFRs have now entered the clinic, but in common with many cancer therapies, resistance develops in most cases. To model this we derived resistant sublines of two FGFR-driven bladder cancer cell lines by long term culture with the FGFR inhibitor PD173074 and explored mechanisms using expression profiling and whole exome sequencing. We identified several resistance-associated molecular profiles. These included HRAS mutation in one case and reversible mechanisms resembling a drug-tolerant persister phenotype in others. Upregulated IGF1R expression in one resistant derivative was associated with sensitivity to linsitinib and a profile with upregulation of a YAP/TAZ signature to sensitivity to the YAP inhibitor CA3 in another. However, upregulation of other potential therapeutic targets was not indicative of sensitivity. Overall, the heterogeneity in resistance mechanisms and commonality of the persister state present a considerable challenge for personalised therapy. Nevertheless, the reversibility of resistance may indicate a benefit from treatment interruptions or re-treatment following disease relapse in some patients. This article is protected by copyright. All rights reserved.

Related Products

Related Targets

EGFR Apoptosis related VEGFR